Sumatriptan vs Rizatriptan

Multiple head-to-head randomized controlled trials and large meta-analyses have compared sumatriptan and rizatriptan for acute migraine treatment. A landmark 2001 meta-analysis by Ferrari et al. in The Lancet, which pooled data from 53 triptan trials involving 24,089 patients, provided the most comprehensive efficacy comparison ^[3]. This analysis found that rizatriptan 10 mg had a slightly higher 2-hour pain-free rate (40%) compared to sumatriptan 100 mg (30%), with a therapeutic gain (difference from placebo) of 27% for rizatriptan vs. 21% for sumatriptan ^[3].

A direct head-to-head randomized trial by Goldstein et al. compared rizatriptan 10 mg to sumatriptan 50 mg and found that rizatriptan provided significantly faster pain relief, with more patients reporting pain relief at 1 hour (38% vs. 28%, p<0.01) ^[6]. By 2 hours, the difference narrowed, with both drugs achieving approximately 67-72% pain relief rates ^[6]. This suggests rizatriptan's primary advantage over sumatriptan may be speed of onset rather than overall efficacy.

The consistency of response is another important metric. Both medications show good consistency across multiple treated attacks, with approximately 67-80% of patients who respond to the first attack also responding to subsequent attacks ^[3][7]. Headache recurrence within 24 hours occurs in approximately 30-40% of patients with sumatriptan and 30-35% with rizatriptan, a difference that is not statistically significant ^[3][6].

Sumatriptan has the broadest range of formulations of any triptan, including oral tablets (25, 50, 100 mg), nasal spray (5, 20 mg), subcutaneous injection (4, 6 mg), and transdermal patches ^[1]. The subcutaneous injection provides the fastest onset (10-15 minutes) and highest efficacy (approximately 70-80% pain-free at 2 hours) of any triptan formulation, making it uniquely effective for severe migraines with nausea or vomiting ^[1][3].

Both sumatriptan and rizatriptan share the typical triptan side effect profile, which includes chest tightness/pressure (triptan sensations), paresthesias (tingling), flushing, dizziness, somnolence, and fatigue ^[1][2][5]. These "triptan sensations" — often described as heaviness, tightness, or pressure in the chest, neck, or throat — are not cardiac in origin in most cases and occur in approximately 2-5% of patients with either drug ^[1][2][3].

In clinical trials, rizatriptan showed a slightly lower overall adverse event rate compared to sumatriptan oral formulations. The Ferrari meta-analysis reported that the incidence of any adverse event was approximately 45% with sumatriptan 100 mg compared to 39% with rizatriptan 10 mg, though the lower sumatriptan 50 mg dose had a more comparable adverse event rate ^[3]. Dizziness occurred in approximately 9% of sumatriptan 100 mg patients vs. 8% with rizatriptan 10 mg. Fatigue and somnolence were slightly more common with sumatriptan ^[3].

Subcutaneous sumatriptan causes injection site reactions (pain, redness, swelling) in up to 60% of patients, and triptan sensations are more common with this route (up to 40%) compared to oral formulations ^[1][5]. This higher side effect burden with injectable sumatriptan must be weighed against its superior efficacy for severe attacks.

Both medications are contraindicated in patients with coronary artery disease, cerebrovascular disease, peripheral vascular disease, uncontrolled hypertension, hemiplegic or basilar migraine, and within 24 hours of another triptan or ergotamine ^[1][2][4]. The vasoconstrictor mechanism that makes triptans effective for migraine creates a theoretical cardiovascular risk in patients with pre-existing vascular disease, though serious cardiovascular events are rare (approximately 1 per 1 million triptan exposures) ^[4][5].

Both sumatriptan and rizatriptan are available as affordable generics. Generic sumatriptan tablets (100 mg, pack of 9 tablets) typically cost $10-$30 with a GoodRx coupon, making it one of the most cost-effective triptan options ^[10]. Generic rizatriptan tablets (10 mg, pack of 9) cost approximately $15-$40 with discount pricing ^[10].

Sumatriptan has a cost advantage in its injectable formulation. Generic sumatriptan injection (6 mg/0.5 mL autoinjectors, pack of 2) costs approximately $30-$80, while no injectable form of rizatriptan exists ^[10]. Brand-name Imitrex (sumatriptan) runs $200-$350 per pack, and brand-name Maxalt (rizatriptan) costs $300-$500 per pack — though generics are dispensed in the vast majority of cases.

Insurance coverage for triptans varies. Most plans cover both generic sumatriptan and generic rizatriptan, often with quantity limits (typically 6-9 tablets per month). Prior authorization may be required for higher quantities or for brand-name products. Both manufacturers offer patient assistance programs for uninsured patients.

Formulation options are a key differentiator in this comparison. Sumatriptan offers the widest variety of delivery options among all triptans: oral tablets (25, 50, 100 mg), nasal spray (5, 20 mg), subcutaneous injection via autoinjector (4, 6 mg), and a needle-free transdermal system ^[1]. This makes sumatriptan uniquely versatile — the injection and nasal spray are particularly valuable for patients whose migraines are accompanied by severe nausea or vomiting that prevents oral medication absorption ^[1][3].

Rizatriptan is available as conventional tablets (5, 10 mg) and an orally disintegrating tablet (Maxalt-MLT, 5, 10 mg) that dissolves on the tongue without water ^[2]. The MLT formulation is convenient for patients on the go or those experiencing nausea, though it is absorbed through the GI tract (not the oral mucosa) and has the same pharmacokinetics as regular tablets ^[2].

Rizatriptan's faster onset of action with oral dosing (peak plasma levels at 1-1.5 hours vs. 2 hours for oral sumatriptan) is a practical advantage when speed matters ^[2][3]. Both medications can be repeated if headache recurs, with a minimum 2-hour interval between doses. Maximum daily doses are: sumatriptan 200 mg oral / 40 mg nasal / 12 mg subcutaneous, and rizatriptan 30 mg oral ^[1][2]. An important drug interaction to note: rizatriptan dose should be reduced to 5 mg in patients taking propranolol, a common migraine preventive ^[2][8].

The choice between sumatriptan and rizatriptan depends on individual migraine characteristics, the importance of speed of relief, formulation preferences, concomitant medications, and cost considerations ^[3][6].

Rizatriptan may be preferred for patients who prioritize the fastest possible onset of oral relief, as head-to-head data show it provides pain relief approximately 30-60 minutes sooner than oral sumatriptan ^[3][6]. Its orally disintegrating tablet is convenient for patients without access to water or those experiencing mild nausea. For patients who find that their migraines escalate quickly, getting effective drug levels faster can mean the difference between treating successfully and having a refractory attack.

Sumatriptan is the better choice when formulation flexibility is important. Its subcutaneous injection is the most effective acute migraine treatment available (any route, any drug) and is invaluable for patients with severe migraines accompanied by vomiting ^[1][3]. The nasal spray provides another non-oral option. Sumatriptan is also generally slightly less expensive as a generic, which may matter for patients treating frequent migraines ^[10].

Patients taking propranolol for migraine prevention should know that rizatriptan requires dose reduction to 5 mg (from the standard 10 mg) due to a pharmacokinetic interaction, whereas sumatriptan has no such interaction ^[2][8]. For patients on propranolol, sumatriptan may be the simpler choice. Patients with cardiovascular risk factors should discuss triptan safety with their provider before using either medication ^[4][5].

Many migraine specialists recommend trying more than one triptan if the first does not provide adequate relief, as response to individual triptans varies significantly between patients ^[3][7]. If one of these medications does not work well for you, switching to the other (or to a different triptan) is a reasonable and evidence-supported strategy.